

Lipid-based nutrient supplements for prevention of child undernutrition: when less may be more

Kathryn G. Dewey¹, Charles D. Arnold¹, K. Ryan Wessells¹, Christine P. Stewart¹

Institute for Global Nutrition and Department of Nutrition, University of California, Davis,
Davis, CA, USA (KGD, CDA, KRW, CPS)

Corresponding Author: Kathryn G. Dewey, Department of Nutrition, University of California,
One Shields Ave., Davis, CA 95616; 530 752 0851; kgdewey@ucdavis.edu

Sources of Support: Bill & Melinda Gates Foundation OPP49817. The funder had no role in the design, implementation, analysis or interpretation of the data.

Short running head: Effects of child MQ- vs SQ-LNS on growth outcomes

Abbreviations: GRADE, Grading of Recommendations Assessment, Development and Evaluation; HAZ, height-for-age z-score; IPD, individual participant data; IYCF, infant and young child feeding; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplements; LQ-LNS, large-quantity lipid-based nutrient supplements; MAM, moderate acute malnutrition; MD, mean difference; MQ-LNS, medium-quantity lipid-based nutrient supplements; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference-for-age z-score; PD, prevalence difference; PR, prevalence ratios; RCT, randomized controlled trial; RNI, recommended nutrient intake; RUTF, ready-to-use therapeutic food; SAM, severe acute malnutrition; SBCC, social and behavior change communication; SMC, seasonal malaria chemoprevention; SQ-LNS, small-quantity lipid based nutrient supplements; UCT, unconditional

cash transfer; WAZ, weight-for-age z-score; WFP, World Food Programme; WHZ, weight-for-height z-score; WLZ, weight-for-length z-score; WSB+, wheat-soy blend plus

Registry and registry number for systematic reviews or meta-analyses: Registered with PROSPERO as CRD42022382448 on December 18, 2022:

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022382448.

Data described in the manuscript are publicly available via referenced articles and the aggregated data and code are available upon request.

1 **Abstract**

2 Background: Both small-quantity (SQ) and medium-quantity (MQ) lipid-based nutrient
3 supplements (LNS) have been used for prevention of child undernutrition. A meta-analysis of 14
4 trials of SQ-LNS vs no LNS showed effects on length-for-age (LAZ, +0.14 (95% confidence
5 interval 0.11, 0.16)) and weight-for-length (WLZ, +0.08 (0.06, 0.10)) z-scores, as well as
6 prevalence ratios (95% CI) for stunting (LAZ<-2, 0.88 (0.85, 0.91)) and wasting (WLZ < -2,
7 0.86 (0.80, 0.93)). However, little is known about the effects of MQ-LNS on growth.

8 Objective: We aimed to examine the effects of preventive MQ-LNS (~250-499 kcal/d) provided
9 at ~6-23 mo of age on growth outcomes compared to no LNS or provision of SQ-LNS.

10 Methods: We conducted a systematic review of studies of MQ-LNS for prevention, and
11 categorized them as providing < 6 mo vs. ≥ 6 mo of supplementation; for the latter category we
12 conducted a meta-analysis, with main outcomes being change in WLZ and LAZ, and prevalence
13 of wasting and stunting.

14 Results: Three studies provided MQ-LNS for 3-5 mo (seasonal) for children 6-36 mo of age, and
15 did not show consistent effects on growth outcomes. Eight studies provided MQ-LNS for 6-18
16 mo, generally starting at 6 mo of age; in the meta-analysis (max total n=13,673), MQ-LNS
17 increased WLZ (+0.09 (0.05, 0.13)) and reduced wasting (0.89 (0.81, 0.97)), but had no effect on
18 LAZ (+0.04 (-0.02, 0.11)) or stunting (0.97 (0.92, 1.02)) compared to no LNS. Two studies
19 directly compared SQ-LNS and MQ-LNS and showed no significant differences in growth
20 outcomes.

21 Conclusions: The current evidence suggests that MQ-LNS offers no added benefits over SQ-
22 LNS, although further studies directly comparing MQ-LNS vs. SQ-LNS would be useful. One

23 possible explanation is incomplete consumption of the MQ-LNS ration and thus lower than

24 desirable intake of certain nutrients.

25 Registry: PROSPERO CRD42022382448:

26 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022382448

27 Key words: malnutrition, infants, home fortification, food supplements, linear growth

28

29 **Introduction**

30 Lipid-based nutrient supplements (LNS) provide multiple micronutrients embedded in a food
31 base that also provides energy, protein and essential fatty acids (1). There is a wide range in the
32 size of the daily ration of LNS provided to young children, depending on whether they are aimed
33 at prevention or treatment of undernutrition (2). The full suite of LNS products includes small-
34 quantity (SQ-LNS, typically 100-120 kcal/d), medium-quantity (MQ-LNS, typically 250-499
35 kcal/d) and large-quantity (LQ-LNS, typically > 500 kcal/d) LNS. The most widely known
36 product is Ready-to-Use Therapeutic Food (RUTF), which is a type of LQ-LNS used for
37 treatment of severe wasting, with the dosage usually based on body weight and treatment goal.
38 On the other end of the spectrum, SQ-LNS are designed for prevention, not treatment, of
39 undernutrition among children 6-23 mo of age. MQ-LNS have been used for both prevention and
40 treatment, and the quantities provided have varied considerably. The ration size of MQ-LNS
41 currently used by the World Food Programme (WFP) and several other agencies is 50 g/d (255
42 kcal/d), generally aimed at prevention of seasonal wasting and/or child undernutrition in food-
43 insecure populations (3).

44 The evidence for preventive effects of SQ-LNS on stunting, wasting, iron-deficiency anemia and
45 mortality is based on meta-analyses of 14-18 randomized controlled trials that included >37,000
46 children 6-23 mo of age in low- and middle-income countries (4-6). This evidence base was
47 rated as “strong” in the 2021 Lancet Series on Maternal and Child Undernutrition (7). By
48 contrast, less is known about the impact of MQ-LNS used for prevention. In a Cochrane review
49 in 2019, Das et al. (8) found no significant differences in growth outcomes between SQ-LNS and
50 MQ-LNS for children 6-23 mo of age when results were stratified by LNS quantity, but data
51 were available for only 4 MQ-LNS trials.

52 This previous evidence thus raised the question of whether there is any advantage of MQ-LNS
53 over SQ-LNS for prevention of undernutrition among children 6-23 mo of age. Given that MQ-
54 LNS is more expensive per daily ration than SQ-LNS (9, 10), answering this question has
55 important programmatic implications. Some studies have suggested that children of this age,
56 especially those < 12 mo of age, are unlikely to consume the full daily ration of MQ-LNS in
57 addition to breast milk and other complementary foods provided by caregivers (11-13). The
58 energy needed from complementary foods, assuming average breast-milk intakes, is only ~200
59 kcal at 6–8 mo, ~300 kcal at 9–11 mo, and ~550 kcal at 12–23 mo of age (14). A daily ration of
60 255 kcal/d from MQ-LNS exceeds or comprises a large percentage of those targets. Thus, when
61 given MQ-LNS, the child may leave a substantial amount of the supplement unconsumed. In
62 Malawi, for example, when MQ-LNS providing 241 kcal/d was provided and the caregiver
63 reported LNS consumption on the day of dietary assessment, average intake of LNS was only
64 ~100 kcal/d at ~9 mo of age (13), meaning that those infants received less than half of the
65 intended amounts of the vitamins and minerals. In Pakistan, only 20.7% of children consumed
66 the full dose of MQ-LNS when offered, even though 81% of caregivers were aware of the
67 recommended dose (12).

68 To provide updated evidence relevant to this question, we aimed to examine the effects of
69 preventive MQ-LNS provided at ~6-23 mo of age on child growth outcomes compared to (1) no
70 provision of LNS and (2) provision of SQ-LNS. To understand the implications of incomplete
71 consumption of the daily ration of MQ-LNS, we also estimated nutrient intakes from MQ-LNS
72 and SQ-LNS under different scenarios.

73

74

75 **Methods**

76 Systematic review and meta-analysis

77 The protocol for this review and meta-analysis was registered as PROSPERO 2022

78 CRD42022382448,

79 https://www.crd.york.ac.uk/prospere/display_record.php?ID=CRD42022382448. The protocol

80 was originally registered on December 18, 2022 and modified on May 19, 2023 to clarify the

81 definition of the control group. We have reported results according to the Preferred Reporting

82 Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (15). A detailed

83 protocol is available on Open Science Framework (16).

84 *Literature search and criteria for inclusion in meta-analysis*

85 We began the search by considering the studies identified by and included in a 2019 Cochrane

86 systematic review and meta-analysis of the provision of preventive LNS for children 6-23 mo of

87 age (8), as well as a series of individual participant data (IPD) analyses that examined the effects

88 of SQ-LNS on the prevention of child undernutrition and promotion of healthy development (5).

89 Then we repeated the database search methods employed in the 2019 Cochrane review to capture

90 any studies published between September 2019 and November 2022. The search strategy used

91 the search strategies set out in Appendix 2 of the aforementioned review (8). There were no

92 language restrictions. We searched the following international electronic bibliographic databases:

93 The Cochrane Library (Cochrane Central Register of Controlled Trials, Cochrane Database of

94 Systematic Reviews), MEDLINE (Ovid, In-Process and Other Non-Indexed Citations Ovid,

95 Epub ahead of print Ovid), EMBASE (Ovid), CINAHL Complete via EBSCOhost, Web of

96 Science Social Sciences Citation Index, Science Citation Index, Conference Proceedings Citation

97 Index-Science, Conference Proceedings Citation Index-Social Sciences), Epistemonikos (current
98 issue), ClinicalTrials.gov, and WHO International Clinical Trials Registry Platform. In addition,
99 we searched relevant regional databases. One of the authors (KRW) reviewed the titles and
100 abstracts of all studies identified, to select all potentially relevant studies for full-text review.
101 Full-text reports of all potentially relevant records were assessed against the inclusion and
102 exclusion criteria detailed below.

103 We included prospective randomized controlled trials conducted in low- or middle-income
104 countries, with MQ-LNS (~250 kcal/d) provided to the intervention group for at least 3 mo
105 between 6 and 23 mo of age. For a trial to be eligible for meta-analysis, a control group that did
106 not receive MQ-LNS had to be available (e.g., comparator/control). The comparator group could
107 have received other non-LNS type of child or household supplementation when the child was 6-
108 23 mo of age, provided the intervention group received the same, e.g., household food ration,
109 fortified blended food during the lean season, etc. Alternatively, the comparator group could
110 have received SQ-LNS. Studies had to include longitudinal follow-up of each child, or repeated
111 cross-sectional data collection. Studies were excluded if they focused primarily on the treatment,
112 not prevention, of malnutrition, e.g., studies in which severe or moderate malnutrition was an
113 inclusion criterion for children in the study. We also excluded studies conducted in a hospitalized
114 population or among children with a pre-existing disease, and studies in which MQ-LNS
115 provision was combined with additional supplemental food or nutrients for the child within a
116 single arm (e.g., MQ-LNS + food rations vs. control), and there was no appropriate comparison
117 group (e.g., food rations alone) that would allow separation of the MQ-LNS effect from effects
118 of the other food or nutrients provided.

119 After initial screening, studies were grouped into 2 categories:

120 (1) MQ-LNS used for < 6 mo (e.g., seasonal use during the lean season)

121 (2) MQ-LNS used for \geq 6 mo for children 6 - 23 mo of age

122 We conducted meta-analyses of studies in the second category, as the types and definitions of
123 outcomes reported in studies in the first category were too heterogeneous for meta-analysis. We
124 conducted two sets of meta-analyses. For the first, MQ-LNS arms were compared with control
125 arms that received similar household-level or child-specific interventions. For the second meta-
126 analysis, the comparator was arms that received SQ-LNS (<125 kcal/d).

127 *Outcomes assessed*

128 The main outcomes for meta-analysis were weight-for-length Z (WLZ) score (sometimes
129 measured as weight-for-height, WHZ), wasting (WLZ or WHZ < -2 SD), length-for-age Z (LAZ)
130 score (sometimes measured as height-for-age, HAZ), and stunting (LAZ or HAZ < -2 SD).
131 Additional outcomes considered (if available for more than 2 studies) were weight-for-age Z
132 (WAZ) score, mid-upper arm circumference-for-age Z (MUACZ) score, head circumference-for-
133 age Z score, cumulative incidence of wasting or low MUAC, underweight (WAZ < -2 SD), small
134 head size (head circumference for age z-score < -2 SD), low MUAC (MUACZ < -2 SD or < 125
135 mm), acute malnutrition (WLZ < -2 SD or MUAC < 125 mm), severe wasting (WLZ < -3 SD),
136 severe stunting (LAZ < -3 SD), very low MUAC (MUACZ < -3 SD or MUAC < 115 mm), and
137 severe acute malnutrition (WLZ < -3 SD or MUAC < 115 mm). All z-scores were calculated
138 using the 2006 WHO Child Growth Standards (17, 18). Each individual study's principal
139 endpoint was used for outcome variables.

140 *Data extraction*

141 A standardized form was used to extract data from the publications of included studies for
142 assessment of study quality and evidence synthesis. Two authors (CDA and KRW) extracted the
143 data. Extracted information included: study setting, participant population and demographics
144 (age at enrollment), study randomization scheme (cluster vs. individual), details of the
145 intervention and control conditions (type and quantity of supplement, duration of
146 supplementation, passive vs. active control, multi-component interventions, etc.), study sample
147 size, primary and secondary outcomes, and information for the assessment of risk of bias.

148 *Risk of bias (quality) assessment*

149 We assessed quality and risk of bias using the criteria outlined in the Cochrane Handbook for
150 Systematic Reviews of Interventions (19) and the Grading of Recommendations Assessment,
151 Development and Evaluation (GRADE) framework (20). Two reviewers (CDA and KRW)
152 independently assessed the risk of bias using the following criteria: random sequence generation,
153 allocation concealment, blinding of participants and personnel, blinding of outcome assessment,
154 incomplete outcome data, selective reporting and other sources of bias. GRADE criteria
155 included: risk of bias, inconsistency of effect, imprecision, indirectness, and publication bias.

156 *Data synthesis and analysis*

157 We used R version 4.1.1 (R Core Team, Vienna, Austria) for all statistical analyses. For each
158 study, intervention groups were combined into LNS and Control groupings by taking the
159 weighted average for means and standard deviations and by using the summed event count and
160 total denominator sample size for binary outcomes. We extracted the endline prevalences and
161 event counts from study publications and completed analysis based on the extracted values. If
162 event count was not available for binary outcomes, it was approximated based on reported

163 prevalence. If standard deviation values were not available for continuous outcomes for a given
164 study, they were approximated based on the weighted averages of standard deviations for the
165 same outcomes within intervention groups reported from comparable trials. Standardized mean
166 difference-in-differences (MD) (from time of start of child supplementation) were estimated and
167 pooled for continuous outcomes, and prevalence ratios (PR) and prevalence differences (PD)
168 were estimated and pooled for binary outcomes, recalibrating to account for baseline differences
169 as needed. Pooling was done using a random effect inverse variance weighting approach and
170 confidence intervals were two-sided at the 95% confidence level. All testing was two-sided and
171 considered significant at the $\alpha=0.05$ level, unless otherwise specified.

172 We explored trial protocol heterogeneity by summarizing the methods, participants,
173 interventions, monitoring approaches, and potential for bias of each study. Studies with protocols
174 that differed substantially from the rest were assessed to determine if they differed in treatment
175 effect, via sensitivity analyses. For statistical heterogeneity we calculated I^2 statistics.

176 Estimated nutrient intakes from MQ-LNS and SQ-LNS under different scenarios

177 To understand the implications of incomplete consumption of the daily ration of MQ-LNS, we
178 calculated the amounts of each nutrient that would be consumed if children ate the full 50g
179 sachet or only half of the sachet (i.e., 25 g/d) of the MQ-LNS formulation used by WFP. For
180 comparison, we also calculated nutrient intakes based on consuming a full sachet of SQ-LNS (20
181 g/d). **Supplemental Table 1** shows the nutrient content of the WFP formulations of MQ-LNS
182 and SQ-LNS, as well as the SQ-LNS formulation used in the most recent research trials (which
183 differs slightly from the WFP formulation), along with the recommended nutrient intake (RNI)
184 values used for these calculations.

185 **Results**

186 Literature search and trial characteristics

187 We screened 2,709 records and assessed 58 reports that met initial screening criteria (**Figure 1**).
188 Of those 58, 24 were excluded because they were not randomized trials, did not use MQ-LNS,
189 were focused only on treating malnutrition, had no appropriate comparison group, were ongoing
190 trials or were systematic reviews. The remaining 34 reports were publications from 11 different
191 studies. Of those 11 studies, 3 were categorized as short-term use of MQ-LNS (< 6 mo) and 8
192 were categorized as using MQ-LNS for ≥ 6 mo.

193 **Table 1** shows the characteristics of the trials in these two categories. The 3 short-term trials
194 were conducted in Chad, Niger and Nigeria (21-23), and all were designed to provide MQ-LNS
195 only during the lean season (generally for 3-5 mo) to children who ranged in age from 6 to 24
196 mo (2 trials) (22, 23) or 6 to 36 mo (1 trial) (21). All 3 were cluster-randomized trials, but the
197 number and types of intervention groups varied. In Chad there were 2 groups: all households
198 received a monthly food package and the intervention households received an additional ration
199 of daily MQ-LNS for the child aged 6-36 mo. In Niger, there were 7 groups in the full study but
200 5 of them received LQ-LNS or Supercereal+ as the child's food ration, leaving 2 groups for the
201 comparisons herein: MQ-LNS + cash transfer vs. cash transfer only. In Nigeria, there were 2
202 groups: all children received seasonal malaria chemoprevention and the intervention group also
203 received MQ-LNS. The same MQ-LNS formulation (46 g) was used in all 3 trials, but in Nigeria
204 the daily amount was a half-ration (23 g) for infants 6-11 mo of age and a full ration for children
205 12-24 mo of age. Two trials (Chad and Nigeria) presented results relevant to both wasting and
206 linear growth, but the Niger study provided data only on acute malnutrition. Because the
207 definition of wasting was different across trials, there were no comparisons for which we had > 2

208 studies, and thus we did not conduct a meta-analysis of the short-term trial results (the findings
209 are presented in narrative form below).

210 The 8 trials that used MQ-LNS for ≥ 6 mo were conducted in Bangladesh (1 trial), Malawi (3
211 trials), Mali (1 trial) and Pakistan (3 trials) (13, 24-31). In most of the trials, children began
212 receiving MQ-LNS at 6 mo of age and the duration of supplementation was 12-18 mo (i.e., until
213 18-24 mo of age); the exception was one study in Pakistan (29) in which children varied in age at
214 enrollment (6-18 mo) and received MQ-LNS for 6-18 mo, i.e., until 24 mo of age. The 3 studies
215 in Malawi were randomized controlled trials with longitudinal follow-up, and the other 5 studies
216 were cluster-randomized trials (4 with longitudinal follow-up and 1 with repeated cross-sectional
217 surveys). All trials included at least one intervention group in which children received MQ-LNS
218 (40-54 g per ration), but in the Bangladesh trial (24), the daily amount was a half-ration (23 g)
219 for infants 6-11 mo of age and a full ration for children 12-24 mo of age. In 6 of the 8 trials, there
220 was at least one control group in which children did not receive any food supplement; these
221 control groups received standard of care, infant and young child feeding (IYCF) counseling
222 and/or delayed intervention except for 1 trial (in Punjab, Pakistan) (31) in which all households
223 (both control and intervention groups) received a cash transfer. The other 2 trials included a
224 study in Malawi (25) in which the comparison groups received either SQ-LNS or a fortified
225 maize-soy flour, and the study in Mali (27) in which all households received a package of
226 interventions that included blanket provision of a fortified blended flour during the lean season
227 for children 6-23 mo of age. In 1 trial in Pakistan (30), the intervention included maternal food
228 supplementation (with wheat-soy blend) in addition to the MQ-LNS provided to children.
229 Prevalence of wasting in the control groups at endline was relatively high: 8% in Mali (27, 28),
230 9% in Malawi (13), 16% in Bangladesh (24), and 10% (31), 21% (29) and 28% (30) in Pakistan.

231 We evaluated risk of bias in the 8 longer-duration trials that were included in the meta-analysis
232 (**Supplemental Table 2, Supplemental Figure 1**). All trials were judged to have low risk of
233 bias for random sequence generation, allocation concealment, incomplete outcome, selective
234 reporting, and “other.” All trials were judged to have high risk of bias for blinding of
235 participants, because blinding was not possible given the nature of the intervention. Risk of bias
236 in outcome assessment was mixed (3 low, 5 high).

237 Anthropometric outcomes

238 *Short-term trials providing MQ-LNS during the lean season*

239 In Chad (21), where all households were included in a general food distribution program, there
240 were no significant differences between the MQ-LNS and control groups in mean WHZ (SD) [-
241 1.05 (0.93) vs. -1.09 (0.95), $p=0.89$], change in MUAC (+0.01 Z-score/mo; 95% CI: -0.02, 0.04;
242 $p = 0.49$) or incidence of wasting [incidence rate ratio (95% confidence interval (CI)): 0.86 (0.67,
243 1.11), $p=0.25$]. The intervention group had a greater gain in HAZ (+0.03 Z-score/mo; 95% CI:
244 0.01, 0.04; $p<0.001$), but stunting prevalence at endline did not differ significantly between
245 groups (46.2 vs 52.3%, odds ratio (95% CI): 0.69 (0.45, 1.07), $p=0.099$).

246 In Niger (22), the only outcomes reported were moderate acute malnutrition (MAM, defined as -
247 $3 \leq \text{WLZ} < -2$ and/or $11.5 \leq \text{MUAC} < 12.5$ cm) and severe acute malnutrition (SAM, defined as
248 $\text{WLZ} < -3$ and/or $\text{MUAC} < 11.5$ cm and/or bipedal edema). Compared to cash transfer alone,
249 provision of MQ-LNS reduced the risk of both MAM and SAM [Cash vs. MQ-LNS+cash, MAM
250 Hazard Ratio = 2.07 (95% CI: 1.52, 2.82), SAM Hazard Ratio = 2.12 (95% CI: 1.26, 3.58)].

251 In Nigeria (23), there was no significant effect of MQ-LNS on mean change (95% CI) in WLZ [-
252 0.41 (-1.01, 0.20)], LAZ [0.16 (-0.44, 0.76)], WAZ [-0.08 (-0.57, 0.42)] or MUACZ [0.26 (-0.12,

253 0.64)], or on the prevalence [PR (95% CI)] of wasting [1.35 (0.69, 2.62), stunting [0.94 (0.45,
254 1.97), underweight [0.97 (0.52, 1.80)] or low MUAC [1.93 (0.17, 22.41)] between the baseline
255 and midline surveys (i.e., at the end of the 4-mo MQ-LNS distribution period). Between baseline
256 and endline surveys (> 6 mo after MQ-LNS distribution had ended), there were also no
257 significant differences in growth outcomes between groups except that the MQ-LNS group had a
258 significantly greater change in MUACZ [0.60 (0.26, 0.94), $p < 0.01$].

259 *Longer-term trials providing MQ-LNS for ≥ 6 mo*

260 The outcomes available for > 2 of the 8 longer-term trials, and thus included in the meta-
261 analysis, were WLZ, wasting, LAZ, stunting, WAZ, and underweight. The comparisons of MQ-
262 LNS vs. Control are shown in **Table 2**. There were significant effects of MQ-LNS on WLZ [MD
263 +0.09 (95% CI: 0.05, 0.13)], wasting [PR 0.89 (95% CI: 0.81, 0.97), PD -1.4 (-2.4, -0.4)] and
264 underweight [PR 0.94 (0.88, 0.99)], but not on LAZ, stunting or WAZ. **Figures 2 and 3** show
265 the forest plots for wasting and stunting PRs, respectively, for MQ-LNS vs Control, and
266 **Supplemental Figures 2-5** show the forest plots for WLZ, LAZ, WAZ and underweight PR. We
267 rated the quality of the evidence for all outcomes as moderate based on GRADE criteria: risk of
268 bias was generally low, heterogeneity was generally low to moderate (Table 2), all trials were
269 directly aimed at evaluating MQ-LNS, and funnel plots revealed no indication of publication
270 bias, but there were relatively few trials (4-8 depending on the outcome) and only 4 countries
271 were represented.

272 Because the trial in Bangladesh used a half-ration of MQ-LNS for children 6-11 mo of age, we
273 conducted a sensitivity analysis excluding that trial, and results remained significant for WLZ
274 [0.08 (0.02, 0.14)], and wasting [PR 0.87 (0.78, 0.98), PD -1.4 (-2.5, -0.2)], became non-
275 significant for underweight PR [0.97 (0.90, 1.04)], and remained non-significant for LAZ [0.01

276 (-0.04, 0.05)], stunting [PR 0.98 (0.93, 1.04)] and WAZ [0.01 (-0.07, 0.09)]. We also conducted
277 a sensitivity analysis excluding the trial in Pakistan in which both mothers and children received
278 supplementation (30), and the results were similar for WLZ [0.10 (95% CI: 0.06, 0.14)], wasting
279 [PR 0.87 (0.78, 0.96), PD -1.4 (-2.5, -0.3)] and underweight [PR 0.93 (0.86, 1.01)], and remained
280 non-significant for LAZ [0.05 (-0.02, 0.13)], stunting [PR 0.95 (0.90, 1.01)] and WAZ [0.10 (-
281 0.02, 0.21)].

282 For comparison, Table 2 also shows the effects of SQ-LNS on the same outcomes, from the
283 previously reported meta-analyses (32). Effects of MQ-LNS on WLZ and wasting PR were
284 similar to those of SQ-LNS; for example, the relative reduction in wasting prevalence was 11%
285 for MQ-LNS and 14% for SQ-LNS. There was a slightly greater PD for MQ-LNS (-1.4
286 percentage points) than for SQ-LNS (-0.6), despite a similar PR, because the wasting prevalence
287 was generally higher in the MQ-LNS study sites (8-28%) than in the SQ-LNS sites (1-15%) (32).
288 For LAZ, WAZ and stunting, however, significant effects were demonstrated for SQ-LNS but
289 not for MQ-LNS. For underweight, effects of MQ-LNS (6% relative reduction) were significant
290 but of smaller magnitude than those for SQ-LNS (13% relative reduction), and there was no
291 significant effect of MQ-LNS on the PD for underweight.

292 Two of the 8 trials (25, 26) allowed for direct comparisons of SQ-LNS and MQ-LNS groups,
293 shown in **Table 3**. There were no significant differences in any of these growth outcomes
294 between groups. A sensitivity analysis was conducted to restrict the type of LNS to milk-
295 containing formulations, which showed similar results (Table 3). For this comparison, we rated
296 the quality of the evidence for all outcomes as low because there were only 2 trials, both
297 conducted in Malawi.

298 *Estimated nutrient intakes from MQ-LNS under different scenarios*

299 Supplemental Table 1 shows the estimated nutrient intakes, as a percentage of the RNI, from a
300 half-ration of MQ-LNS (25 g/d) or a full ration of SQ-LNS (20 g/d). In terms of nutrient
301 shortfalls, the most problematic nutrients (**Table 4**) are iron and calcium: the half-ration of MQ-
302 LNS would provide only 23% (at 6-12 mo) and 36% (at 12-23 mo) of the RNI for iron, and only
303 48% (at 6-12 mo) and 30% (at 12-23 mo) of the RNI for calcium. The half-ration of MQ-LNS
304 would also fall short of the RNI for zinc (64% of the RNI at 12-23 mo), vitamin A (70% of the
305 RNI at both 6-12 and 12-23 mo), and thiamin (83% of the RNI at 6-12 mo and 50% of the RNI at
306 12-23 mo).

307 **Discussion**

308 In this systematic review of studies in which MQ-LNS was used for prevention of child
309 undernutrition, we identified 3 eligible trials that examined supplementation for 3-5 mo during
310 the lean season and were targeted at children 6-24 or 6-36 mo of age, and 8 longer-duration trials
311 that generally provided MQ-LNS starting at 6 mo of age for a duration of 6-18 mo and met our
312 criteria for meta-analysis. The 3 short-term trials did not show consistent effects on child growth
313 outcomes. In the meta-analysis of the longer-term trials, there was a positive effect on WLZ
314 (+0.09) and relative reductions in wasting (11%) and underweight (6%) in the MQ-LNS groups
315 compared to control, but no effects on LAZ or stunting. Previous meta-analyses of SQ-LNS vs
316 control also showed effects on WLZ (+0.08), wasting (14% reduction) and underweight (13%
317 reduction), but SQ-LNS also had an impact on LAZ (+0.14) and stunting (12% reduction) (32).
318 In two trials that directly compared SQ-LNS and MQ-LNS, there were no significant differences
319 in these growth outcomes. These results suggest no evidence of superiority of MQ-LNS over
320 SQ-LNS for prevention of wasting, and less impact of MQ-LNS on linear growth and stunting.

321 The evidence base for MQ-LNS is considerably smaller and more heterogeneous than is the case
322 for SQ-LNS. The MQ-LNS vs. control meta-analysis results are based on 4-7 trials (depending
323 on the outcome) in 4 countries and a total sample size of <14,000, whereas the SQ-LNS vs.
324 control meta-analysis is based on 14 trials in 9 countries and a total sample size of ~37,000
325 children. The evidence base for short-term MQ-LNS trials aimed at prevention of seasonal
326 undernutrition is very small, with only 3 trials and a total of only ~4,300 children. Results of
327 those 3 trials were mixed. In Niger, the MQ-LNS group had a lower risk of both MAM and
328 SAM, but in Chad and Nigeria, there were no significant effects on WLZ/WHZ or wasting.
329 There were positive effects of MQ-LNS on linear growth in Chad, but no such effects were
330 observed in Nigeria and linear growth outcomes were not reported in Niger. Thus, it is difficult
331 to draw conclusions about the effectiveness of short-term seasonal supplementation for
332 prevention of child undernutrition.

333 The evidence for direct comparisons of SQ-LNS and MQ-LNS is limited to 2 trials, both
334 conducted in Malawi in contexts in which there has been little impact of either supplement
335 (compared to control groups) on growth outcomes (25, 26). The reasons for this lack of response
336 in Malawi are unclear but may be related to high levels of inflammation and infection among
337 infants and young children in this setting (33), which may constrain a growth response to
338 nutritional supplementation. Additional studies directly comparing SQ-LNS and MQ-LNS for
339 prevention of child undernutrition in other settings are needed.

340 The contexts in which the MQ-LNS and SQ-LNS trials were conducted varied considerably.
341 Most of the MQ-LNS trials were conducted in countries with high levels of food insecurity.
342 Among the 14 SQ-LNS trials, 7 were conducted in populations in which >30% of households
343 reported moderate-to-severe food insecurity at baseline (32). Although the level of food

344 insecurity could potentially influence the effectiveness of supplementation, the IPD meta-
345 analysis indicated that household food insecurity did not modify the effects of SQ-LNS on WLZ,
346 LAZ, wasting or stunting (32). In other words, the impact of SQ-LNS on these outcomes was
347 evident even among children in households with moderate-to-severe food insecurity. Thus, it
348 seems unlikely that greater levels of food insecurity in the MQ-LNS trials explains their lack of
349 impact (vs. control) on linear growth or stunting.

350 Four of the 8 longer-term MQ-LNS trials were carried out within community-based programs
351 that included other components, such as health and nutrition services (27, 29, 30), cash transfers
352 (31) or maternal nutritional supplementation (30). Similarly, 6 of the 14 SQ-LNS trials were
353 conducted within existing community-based or clinic-based programs. Therefore, the meta-
354 analysis results for both SQ- and MQ-LNS reflect impact across the spectrum from efficacy trials
355 to effectiveness studies in a real-world context. These two meta-analyses are also comparable
356 with regard to the age at which supplementation began (generally at 6 mo) and the duration of
357 supplementation (generally 12-18 mo).

358 It may seem counter-intuitive that a larger quantity of LNS would have less of an impact on
359 linear growth than a smaller quantity. However, a key consideration with regard to efficacy is the
360 actual intake of micronutrients and essential fatty acids from the supplement by the target child.
361 For children in this age range, particularly those < 12 mo of age, the full daily ration of MQ-LNS
362 (220-280 kcal/d) may be too large in relation to energy needs, particularly for 6-11 mo olds who
363 require only ~200-300 kcal/d from complementary foods. This could lead to incomplete
364 consumption of the supplement and thus a lower than intended intake of micronutrients and fatty
365 acids. There is evidence from several studies that children offered MQ-LNS often consume far
366 less than the daily ration (11-13). As we have demonstrated, if a child consumes only half of a 50

367 g ration of MQ-LNS, the amounts of certain key nutrients (iron, calcium, zinc, vitamin A and
368 thiamin) would fall well short of the recommended intakes. This may not be of concern if the rest
369 of the child's diet provides those nutrients in adequate amounts, but that is unlikely to be the case
370 for iron, calcium and zinc, which are the most limiting nutrients in complementary food diets
371 (34, 35). As a result, the growth response to MQ-LNS may be less than expected, especially for
372 linear growth.

373 In conclusion, the current evidence suggests that MQ-LNS offers no added benefits over SQ-
374 LNS for prevention of child undernutrition. One possible explanation is incomplete consumption
375 of the MQ-LNS ration and thus lower than desirable intake of certain key nutrients. Given that
376 MQ-LNS is more expensive per daily ration than SQ-LNS, this has important programmatic
377 implications. Further research is needed, particularly rigorous research on the seasonal use of
378 MQ-LNS, the use of MQ-LNS in highly food insecure settings, and studies directly comparing
379 MQ-LNS vs. SQ-LNS.

380 **Acknowledgments**

381 We thank members of the SQ-LNS Task Force for input during the design and implementation
382 of the systematic review and meta-analysis.

383 The authors' responsibilities were as follows—KGD: drafted the manuscript with input from
384 other coauthors; KRW, CDA, KGD, and CPS: wrote the statistical analysis plan; KRW and
385 CDA: compiled the data; CDA: conducted the data analysis; and all authors: read, contributed to,
386 and approved the final manuscript; KGD is responsible for final content.

387

388 Supported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD). All authors report no
389 conflicts of interest.

390 **References**

- 391 1. Arimond M, Zeilani M, Jungjohann S, Brown KH, Ashorn P, Allen LH, Dewey KG.
392 Considerations in developing lipid-based nutrient supplements for prevention of undernutrition:
393 experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. *Matern*
394 *Child Nutr* 2015;11 31-61.
- 395 2. Small-quantity lipid-based nutrient supplements. FAQs. Available at:
396 <https://sqlns.ucdavis.edu/> Accessed on: 28 December 2022.
- 397 3. World Food Programme. Technical Specifications for Lipid-Based Nutrient Supplement -
398 Medium Quantity (LNS-MQ). Version 3.0 (2021). Available at:
399 <https://docs.wfp.org/api/documents/WFP-0000104981/download/>. Accessed on: 12 May 2023.
- 400 4. Stewart CP, Wessells KR, Arnold CD, Huybregts L, Ashorn P, Becquey E, Humphrey
401 JH, Dewey KG. Lipid-based nutrient supplements and all-cause mortality in children 6-24
402 months of age: a meta-analysis of randomized controlled trials. *Amer J Clin Nutr* 2020;111:207-
403 18.
- 404 5. Dewey KG, Stewart CP, Wessells KR, Prado EL, Arnold CD. Small-quantity lipid-based
405 nutrient supplements for the prevention of child malnutrition and promotion of healthy
406 development: overview of individual participant data meta-analysis and programmatic
407 implications. *Am J Clin Nutr* 2021;114:3S-14S.
- 408 6. Dewey KG, Arnold CD, Wessells KR, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H,
409 Arnold BF, Ashorn P, Ashorn U, et al. Preventive small-quantity lipid-based nutrient
410 supplements reduce severe wasting and severe stunting among young children: an individual

- 411 participant data meta-analysis of randomized controlled trials. *Am J Clin Nutr*
412 2022;10.1093/ajcn/nqac232.
- 413 7. Keats EC, Das JK, Salam RA, Lassi ZS, Imdad A, Black RE, Bhutta ZA. Effective
414 interventions to address maternal and child malnutrition: an update of the evidence. *Lancet Child*
415 *Adolesc Health* 2021;5:367-84.
- 416 8. Das JK, Salam RA, Hadi YB, Sadiq Sheikh S, Bhutta AZ, Weise Prinzo Z, Bhutta ZA.
417 Preventive lipid-based nutrient supplements given with complementary foods to infants and
418 young children 6 to 23 months of age for health, nutrition, and developmental outcomes.
419 *Cochrane Database Syst Rev* 2019;5:CD012611.
- 420 9. United Nations Children's Fund (UNICEF). UNICEF Supply Catalogue. LNS-SQ Lipid
421 Nut. Suppl. Sml 20g/CAR-600. S0000323. Available at:
422 <https://supply.unicef.org/s0000323.html>. Accessed on: 15 June 2023.
- 423 10. United Nations Children's Fund (UNICEF). UNICEF Supply Catalogue. LNS-MQ Lipid
424 Nut. Suppl. Med 50g/CAR-300. S0000324. Available at:
425 <https://supply.unicef.org/s0000324.html>. Accessed on: 15 June 2023.
- 426 11. Hemsworth J, Kumwenda C, Arimond M, Maleta K, Phuka J, Rehman AM, Vosti SA,
427 Ashorn U, Filteau S, Dewey KG, et al. Lipid-based nutrient supplements increase energy and
428 macronutrient intakes from complementary food among Malawian infants. *J Nutr* 2016;146:326-
429 34.
- 430 12. Zaidi S, Das JK, Khan GN, Najmi R, Shah MM, Soofi SB. Food supplements to reduce
431 stunting in Pakistan: a process evaluation of community dynamics shaping uptake. *BMC Public*
432 *Health* 2020;20:1046.

- 433 13. Maleta KM, Phuka J, Alho L, Cheung YB, Dewey KG, Ashorn U, Phiri N, Phiri TE,
434 Vosti SA, Zeilani M, et al. Provision of 10-40 g/d lipid-based nutrient supplements from 6 to 18
435 months of age does not prevent linear growth faltering in Malawi. *J Nutr* 2015;145:1909-15.
- 436 14. PAHO/WHO (Pan American Health Organization/World Health Organization). 2003.
437 Guiding principles for complementary feeding of the breastfed child. Washington, DC: PAHO.
- 438 15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer
439 L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline
440 for reporting systematic reviews. *BMJ* 2021;372:n71.
- 441 16. Wessells KR, Stewart C, Arnold CD, Dewey K, Prado E. Modifiers of the effect of LNS
442 provided to infants and children 6 to 24 months of age on growth, anemia, micronutrient status
443 and development outcomes. Open Science Framework. Available from: <https://osf.io/ymsfu>.
- 444 17. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards:
445 Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass
446 index-for-age: Methods and development. Geneva: World Health Organization, 2006.
- 447 18. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Head
448 circumference-for-age, arm circumference-for-age, triceps skinfold-for-age and subscapular
449 skinfold-for-age: Methods and development. Geneva: World Health Organization, 2007.
- 450 19. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews for Interventions*,
451 Version 5.1.0. The Cochrane Collaboration 2011. Available from www.handbook.cochrane.org.

- 452 20. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-
453 Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin*
454 *Epidemiol* 2011;64:401-6.
- 455 21. Huybregts L, Hougbe F, Salpeteur C, Brown R, Roberfroid D, Ait-Aissa M, Kolsteren
456 P. The effect of adding ready-to-use supplementary food to a general food distribution on child
457 nutritional status and morbidity: a cluster-randomized controlled trial. *PLoS Med*
458 2012;9:e1001313.
- 459 22. Langendorf C, Roederer T, de Pee S, Brown D, Doyon S, Mamaty AA, Toure LW,
460 Manzo ML, Grais RF. Preventing acute malnutrition among young children in crises: a
461 prospective intervention study in Niger. *PLoS Med* 2014;11:e1001714.
- 462 23. Ward A, Guillot A, Nepomnyashchiy LE, Graves JC, Maloney K, Omoniwa OF,
463 Emegbuonye L, Opondo C, Kerac M, Omoluabi E, et al. Seasonal malaria chemoprevention
464 packaged with malnutrition prevention in northern Nigeria: A pragmatic trial (SMAMP study)
465 with nested case-control. *PloS one* 2019;14:e0210692.
- 466 24. Christian P, Shaikh S, Shamim AA, Mehra S, Wu L, Mitra M, Ali H, Merrill RD,
467 Choudhury N, Parveen M, et al. Effect of fortified complementary food supplementation on child
468 growth in rural Bangladesh: a cluster-randomized trial. *Int J Epidemiol* 2015;44:1862-76.
- 469 25. Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, Ashorn P.
470 Complementary feeding with fortified spread and incidence of severe stunting in 6- to 18-month-
471 old rural Malawians. *Arch Pediatr Adolesc Med* 2008;162:619-26.
- 472 26. Mangani C, Maleta K, Phuka J, Cheung YB, Thakwalakwa C, Dewey K, Manary M,
473 Puumalainen T, Ashorn P. Effect of complementary feeding with lipid-based nutrient

- 474 supplements and corn-soy blend on the incidence of stunting and linear growth among 6- to 18-
475 month-old infants and children in rural Malawi. *Matern Child Nutr* 2015;11 Suppl 4:132-43.
- 476 27. Adubra L, Le Port A, Kameli Y, Fortin S, Mahamadou T, Ruel MT, Martin-Prevel Y,
477 Savy M. Conditional cash transfer and/or lipid-based nutrient supplement targeting the first 1000
478 d of life increased attendance at preventive care services but did not improve linear growth in
479 young children in rural Mali: results of a cluster-randomized controlled trial. *American Journal*
480 *of Clinical Nutrition* 2019;110:1476-90.
- 481 28. Adubra L. Impact d'un transfert monétaire et/ou d'un supplément nutritionnel pour la
482 prévention du retard de croissance du jeune enfant en milieu rural au Mali: analyse d'un essai
483 randomisé par clus-ters. *Santé publique et épidémiologie*. Sorbonne Université,2019. Français.
484 NNT:2019SORUS447. Available online at: <https://theses.hal.science/tel-02931883v1/document>.
485 Accessed: 15 July 2022.
- 486 29. Khan GN, Kureishy S, Ariff S, Rizvi A, Sajid M, Garzon C, Khan AA, de Pee S, Soofi
487 SB, Bhutta ZA. Effect of lipid-based nutrient supplement-Medium quantity on reduction of
488 stunting in children 6-23 months of age in Sindh, Pakistan: A cluster randomized controlled trial.
489 *PLoS One* 2020;15:e0237210.
- 490 30. Soofi S, Khan G, Ariff S, Ihtesham Y, Tanimoune M, Rizvi A, Sajid M, Garzon C, de
491 Pee S, Bhutta Z. Effectiveness of nutritional supplementation during the first 1000-days of life to
492 reduce child undernutrition: A cluster randomized controlled trial in Pakistan. *The Lancet*
493 *Regional Health - Southeast Asia* 2022;4.
- 494 31. Soofi SB, Ariff S, Khan GN, Habib A, Kureishy S, Ihtesham Y, Hussain M, Rizvi A,
495 Sajid M, Akbar N, et al. Effectiveness of unconditional cash transfers combined with lipid-based

- 496 nutrient supplement and/or behavior change communication to prevent stunting among children
497 in Pakistan: a cluster randomized controlled trial. *American Journal of Clinical Nutrition*
498 2022;115:492-502.
- 499 32. Dewey KG, Wessells KR, Arnold CD, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H,
500 Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity
501 lipid-based nutrient supplementation on child growth: an individual participant data meta-
502 analysis of randomized controlled trials. *Amer J Clin Nutr* 2021;114 (Suppl 1):15S-42S.
- 503 33. Luoma J, Adubra L, Ashorn P, Ashorn U, Bendabenda J, Dewey KG, Hallamaa L,
504 Coghlan R, Horton WA, Hyoty H, et al. Association between asymptomatic infections and linear
505 growth in 18-24-month-old Malawian children. *Matern Child Nutr* 2023;19:e13417.
- 506 34. Beal T, White JM, Arsenault JE, Okronipa H, Hinnouho GM, Murira Z, Torlesse H, Garg
507 A. Micronutrient gaps during the complementary feeding period in South Asia: A
508 Comprehensive Nutrient Gap Assessment. *Nutr Rev* 2021;79:26-34.
- 509 35. White JM, Beal T, Arsenault JE, Okronipa H, Hinnouho GM, Chimanya K, Matji J, Garg
510 A. Micronutrient gaps during the complementary feeding period in 6 countries in Eastern and
511 Southern Africa: a Comprehensive Nutrient Gap Assessment. *Nutr Rev* 2021;79:16-25.
- 512 36. World Food Programme. Technical Specifications for Lipid-Based Nutrient Supplement -
513 Small Quantity (LNS-SQ). Version 2.0 (adopted 2020). Available at:
514 <https://docs.wfp.org/api/documents/WFP-0000106806/download/>. Accessed on: 3 December
515 2021.
- 516 37. Dewey KG, Mridha MK, Matias SL, Arnold CD, Cummins JR, Khan MS, Maalouf-
517 Manasseh Z, Siddiqui Z, Ullah MB, Vosti SA. Lipid-based nutrient supplementation in the first

518 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial. Am J Clin

519 Nutr 2017;105:944-57.

520

Table 1. Characteristics of studies included in the systematic review and meta-analysis

Country, years of study, study name, author date	Study design	Intervention groups ¹	LNS product(s)	Age at start of supplementation (duration of supplementation)	Outcomes assessed
MQ-LNS used for < 6 mo					
Chad, 2010, (Huybregts 2012) (21)	Cluster randomized controlled pragmatic trial, longitudinal follow-up	(1) Intervention (n=458) vs. (2) control (n=613): All households received a monthly food package. Intervention households (child 6-36 mo) also received MQ-LNS for 4 mo (June - October).	MQ-LNS (Plumpy'Doz, 46 g, 250 kcal/d)	6-36 mo (4 mo)	Change in WHZ, HAZ, MUAC; prevalence of stunting; cumulative incidence of acute malnutrition or wasting
Niger, 2011, (Langendorf 2014) (22)	Cluster partially-randomized controlled trial, longitudinal follow-up	(1) LQ-LNS, (2) LQ-LNS + cash transfer, (3) MQ-LNS + cash transfer n=1089 , (4) Supercereal plus + cash transfer, (5) Supercereal plus + family food ration, (6) Supercereal plus, (7) cash transfer only (n=680) . LNS distributed August – December.	MQ-LNS (Plumpy'Doz, 46 g, 250 kcal/d); LQ-LNS (Supplementary Plumpy, 92 g, 500 kcal/d)	~6-24 mo (5 mo max)	Incidence of SAM and MAM
Nigeria, 2014, (Ward 2019) (23)	Two-cluster randomized controlled pragmatic trial, repeated cross-sectional household surveys	(1) Seasonal malaria chemoprevention (SMC) (n=803) vs. (2) SMC + SQ/MQ-LNS (n=650) . LNS distributed August – November.	MQ-LNS (Plumpy'Doz, half-dose from 6-11 mo (~23 g, 125 kcal/d); full-dose 12-24 mo (46 g, 250 kcal/d))	6-24 mo (4 mo)	WLZ, LAZ, WAZ, MUACZ; prevalence of wasting, stunting, underweight, low MUAC and SAM
MQ-LNS used for > 6 mo for children 6 - 23 mo of age					
Bangladesh, 2012-2014, JiVitA-4, (Christian 2015) (24)	Cluster RCT, longitudinal follow-up	(1) SQ/MQ-LNS (n=3160), (2) control (n=1438) , (3) wheat-soy blend. All groups received IYCF counseling.	MQ-LNS (Plumpy'Doz, chickpea-based LNS or rice-lentil LNS): 1/2 dose from 6-11 mo (~23 g, 125 kcal/d), full-dose 12-18 mo (46 g, 250 kcal/d)	6 mo (12 mo)	Change in WLZ, LAZ, , WAZ; prevalence of wasting, stunting, underweight; cumulative incidence of wasting
Malawi, 2004-	RCT, longitudinal	(1) SQ-LNS (n=60), (2) MQ-LNS	SQ-LNS (25 g, 130 kcal/d)	6 mo (12 mo)	Change in WLZ, LAZ, WAZ;

2005, (Phuka 2008) (25)	follow-up	(n=61) , (3) micronutrient fortified maize-soy flour	and MQ-LNS (50 g, 260 kcal/d); peanut- and milk-based LNS; same amounts of micronutrients (except Ca) provided to each group		incidence of severe or moderate to severe wasting, stunting and underweight
Malawi, 2008-2010, (Mangani 2015) (26)	RCT, longitudinal follow-up	(1) MQ-LNS containing milk (n=212), (2) MQ-LNS without milk (n=210), (3) corn-soy blend, (4) control (delayed intervention, n=209)	MQ-LNS (54 g, 280 kcal/d); peanut + milk or soy based LNS	6 mo (12 mo)	Change in WLZ, LAZ, WAZ; incidence of severe wasting, any stunting, severe stunting, very severe stunting (LAZ < -3.5 SD), severe underweight;; prevalence of severe wasting, any stunting, severe stunting, and very severe stunting
Malawi, 2009-2012, (Maleta 2015) (13)	RCT, longitudinal follow-up	(1) SQ-LNS containing milk (10 g/d, n=321), (2) SQ-LNS containing milk (20 g/d, n=322), (3) SQ-LNS without milk (20 g/d, n=323), (4) MQ-LNS containing milk (40 g/d, n=322), (5) MQ-LNS without milk (40 g/d, n=324), (6) control (n=320)	SQ-LNS with or without milk (10 or 20 g/d, ~55-118 kcal/d) and MQ-LNS with or without milk (40 g, 240 kcal/d); same amounts of micronutrients provided to each group	6 mo (12 mo)	Change in WLZ, LAZ, WAZ, MUACZ; incidence of wasting, severe wasting; stunting, severe stunting; underweight, severe underweight
Mali, 2013-2016, (Adubra 2019) (27, 28)	Cluster RCT, repeated cross-sectional surveys	(1) Community health & nutrition program (SNACK) (n=1278), (2) SNACK + Cash n=1223), (3) SNACK + MQ-LNS (n=1289), (4) SNACK + Cash + MQ-LNS (n=1256)	MQ-LNS (Plumpy'Doz, 46 g, 250 kcal/d)	6 mo (18 mo)	WLZ, HAZ ; prevalence of wasting, stunting
Pakistan (Sindh Cohort 2), 2014-2016, (Khan 2020) (29)	Cluster RCT, longitudinal follow-up	(1) MQ-LNS (n=419) vs. (2) standard of care (n=451)	MQ-LNS (Wawamum, 50 g, 255 kcal/d); chickpea- and milk-based formulation	6-18 mo (6-18 mo)	Prevalence of wasting, stunting, underweight
Pakistan (Sindh Cohort 1), 2015-2018, (Soofi 2022) (30)	Cluster RCT, longitudinal follow-up	(1) WSB+ in pregnancy and 6 mo post-partum, child MQ-LNS 6-23 mo (n=705) vs. (2) standard of care (n=753)	MQ-LNS (Wawamum, 50 g, 255 kcal/d); chickpea- and milk-based formulation	6 mo (18 mo)	WLZ, LAZ, WAZ; prevalence of wasting, stunting, underweight
Pakistan (Punjab), 2017-2019, (Soofi	Cluster RCT, longitudinal follow-up	(1) Unconditional cash transfer (UCT, n=434), (2) UCT + SBCC (n=433), (3) UCT + MQ-LNS	MQ-LNS (Wawamum, 50 g, 225 kcal/d); chickpea- and milk-based formulation	6 mo (18 mo)	WLZ, LAZ, WAZ; prevalence of wasting, stunting, underweight

2022) (31)		(n=430), (4) UCT + MQ-LNS + SBCC (n=432)			
------------	--	-------------------------------------------------	--	--	--

HAZ, height-for-age z-score; IYCF, infant and young child feeding; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplement; LQ-LNS, large-quantity lipid-based nutrient supplement; MAM, moderate acute malnutrition; MQ-LNS, medium-quantity lipid-based nutrient supplement; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z-score; RCT, randomized controlled trial; SAM, severe acute malnutrition; SBCC, social and behavior change communication; SMC, seasonal malaria chemoprevention; SQ-LNS, small-quantity lipid-based nutrient supplement; UCT, unconditional cash transfer; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score; WLZ, weight-for-length z-score; WSB+, wheat-soy blend plus.

¹Intervention groups used in this meta-analysis are in bold; sample sizes (n) are the number of children randomized to each group, except for the study in Nigeria (Ward) for which the numbers of children in the midline survey are listed.

Table 2. Main effects of MQ-LNS (relative to Control) and SQ-LNS (relative to Control) on growth outcomes¹

Outcome	MQ-LNS vs Control			SQ-LNS vs Control (from IPD meta-analysis (32))		
	N (# comparisons) ²	MD, PR or PD ³ (95% CI)	<i>I</i> ²⁽⁴⁾	N (# comparisons)	MD, PR or PD ³ (95% CI)	<i>I</i> ²⁽⁴⁾
WLZ (MD)	11,603 (5)	0.09 (0.05, 0.13) P<0.001	0.03	36,608 (17)	0.08 (0.06, 0.10) P<0.001	0.51
Wasting (PR)	13,673 (7)	0.89 (0.81, 0.97) P=0.008	0.00	36,311 (16)	0.86 (0.80, 0.93) P<0.001	0.00
Wasting (PD)	13,673 (7)	-1.4 (-2.4, -0.4) P=0.008	0.00	36,311 (16)	-0.6 (-1.0, -0.1) P=0.01	0.12
LAZ (MD)	11,812 (5)	0.04 (-0.02, 0.11)	0.56	36,795 (17)	0.14 (0.11, 0.16) P<0.001	0.65
Stunting (PR)	13,954 (8)	0.97 (0.92, 1.02)	0.34	36,795 (17)	0.88 (0.85, 0.91) P<0.001	0.49
Stunting (PD)	13,954 (8)	-1.2 (-3.5, 1.0)	0.32	36,795 (17)	-5.0 (-5.9, -4.1) P<0.001	0.54
WAZ (MD)	6,683 (4)	0.07 (-0.03, 0.17)	0.63	36,787 (17)	0.13 (0.11, 0.15) P<0.001	0.66
Underweight (PR)	8,550 (6)	0.94 (0.88, 0.99) P=0.028	0.06	36,787 (17)	0.87 (0.83, 0.97) P<0.001	0.42
Underweight (PD)	8,550 (6)	-0.7 (-4.2, 2.7)	0.66	36,787 (17)	-3.1 (-3.8, -2.3) P<0.001	0.60

¹LAZ, length-for-age z score; MQ-LNS, medium-quantity lipid-based nutrient supplement; MD, mean difference; PD, prevalence difference (percentage points); PR, prevalence ratio; WAZ, weight-for-age z score; WLZ, weight-for-length z score.

²The maximum number of comparisons was 8 (7 studies, with 2 comparisons for 1 of those studies (31)), for stunting. For the other outcomes, prevalence of wasting was not reported in 1 study (26), prevalence of underweight was not reported in 2 studies (26, 27), and z-score values from some studies were not available (29) or were not calculable as difference-in-difference estimates (31).

³For continuous outcomes, values are MDs: MQ-LNS – control (95% CIs). For binary outcomes, values are PR and PDs: MQ-LNS compared with control (95% CIs). P-values correspond to the pooled main effect 2-sided superiority testing of the intervention effect estimate and 95% CI.

⁴*I*² describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, 0.3–0.6 may be considered moderate heterogeneity.

Table 3. Effects of MQ-LNS vs SQ-LNS on growth outcomes in trials with direct comparisons of these 2 interventions¹

Outcome	MQ-LNS vs SQ-LNS				
	LNS	Study ²	N	MD or PR (95% CI) ³	I ² (⁴)
WLZ (MD)	All types	Phuka	118	0.10 (-0.26, 0.46)	0.00
		Maleta	1,180	0.06 (-0.05, 0.18)	
		Pooled	1,298	0.07 (-0.04, 0.18)	
	Milk-LNS	Phuka	118	0.10 (-0.26, 0.46)	0.00
		Maleta	697	0.09 (-0.06, 0.25)	
		Pooled	815	0.09 (-0.05, 0.24)	
Wasting (PR)	All types	Phuka	118	2.26 (0.61, 8.30)	0.72
		Maleta	1,305	0.60 (0.39, 0.92)	
		Pooled	1,423	1.00 (0.28, 3.56)	
	Milk-LNS	Phuka	118	2.26 (0.61, 8.30)	0.70
		Maleta	774	0.60 (0.34, 1.05)	
		Pooled	892	1.01 (0.28, 3.63)	
LAZ (MD)	All types	Phuka	106	0.05 (-0.33, 0.43)	0.00
		Maleta	1,180	-0.05 (-0.17, 0.07)	
		Pooled	1,286	-0.04 (-0.15, 0.07)	
	Milk-LNS	Phuka	106	0.05 (-0.33, 0.43)	0.00
		Maleta	697	-0.02 (-0.17, 0.14)	
		Pooled	803	-0.01 (-0.15, 0.14)	
Stunting (PR)	All types	Phuka	106	0.72 (0.36, 1.45)	0.00
		Maleta	952	1.03 (0.85, 1.26)	
		Pooled	1,058	1.01 (0.83, 1.22)	
	Milk-LNS	Phuka	106	0.72 (0.36, 1.45)	0.00
		Maleta	570	1.05 (0.79, 1.39)	
		Pooled	676	1.00 (0.77, 1.30)	
WAZ (MD)	All types	Phuka	113	0.18 (-0.19, 0.54)	0.00
		Maleta	1,180	0.04 (-0.08, 0.16)	
		Pooled	1,293	0.05 (-0.06, 0.16)	
	Milk-LNS	Phuka	113	0.18 (-0.19, 0.54)	0.00
		Maleta	697	0.07 (-0.08, 0.23)	
		Pooled	810	0.09 (-0.06, 0.23)	
Underweight (PR)	All types	Phuka	113	1.02 (0.62, 1.68)	0.00
		Maleta	1,146	0.84 (0.61, 1.14)	
		Pooled	1,259	0.88 (0.68, 1.15)	
	Milk-LNS	Phuka	113	1.02 (0.62, 1.68)	0.00
		Maleta	678	0.99 (0.65, 1.52)	
		Pooled	791	1.00 (0.73, 1.38)	

¹LAZ, length-for-age z score; MQ-LNS, medium-quantity lipid-based nutrient supplement; MD, mean difference; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z score; WLZ, weight-for-length z score.

²The 2 studies were Phuka et al. (25) and Maleta et al. (13)

³For continuous outcomes, values are MDs: MQ-LNS – SQ-LNS (95% CIs). For binary outcomes, values are PRs: MQ-LNS compared with SQ-LNS (95% CIs). Note: prevalence differences (percentage points)

did not differ between MQ-LNS and SQ-LNS groups: wasting: 0.3 (-9.3, 9.9), $p=0.951$; stunting: -0.1 (-5.6, 5.4), $p=0.979$; underweight: -2.2 (-6.0, 1.6), $p=0.264$.

I^2 describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, 0.3–0.6 may be considered moderate heterogeneity.

Table 4. Percentage of recommended nutrient intakes for several key nutrients provided by a half-ration of MQ-LNS or a full ration of SQ-LNS^{1,2}

Nutrient	6-12 months		1-3 years	
	25 g of MQ-LNS (128-140 kcal)	SQ-LNS (20 g) (110-124 kcal)	25 g of MQ-LNS (128-140 kcal)	SQ-LNS (20 g) (110-124 kcal)
Iron	23	55 (82) ³	36	86 (129) ³
Calcium	48	≥100	30	62
Zinc	95	≥100	64	≥100
Vitamin A	70	≥100	70	≥100
Thiamin	83	≥100	50	60 (≥ 100)

¹ MQ-LNS, medium-quantity lipid-based nutrient supplement; SQ-LNS, small-quantity lipid-based nutrient supplement

² % of recommended nutrient intakes for iron, calcium, zinc, vitamin A and thiamin, based on WFP formulations for SQ-LNS and MQ-LNS (see Supplemental Table 1) (3, 36)

³ Values in parentheses are based on the iLiNS SQ-LNS formulation that includes 9 mg iron/20 g and 0.5 mg of thiamin/20 g (37)

Figure Legends

Figure 1: Study flow diagram. MQ-LNS, medium-quantity lipid-based nutrient supplements, SQ-LNS, small-quantity lipid-based nutrient supplements; RCT, randomized controlled trial.

Figure 2: Forest plot of effect of MQ-LNS vs. control on wasting prevalence. MQ-LNS, medium-quantity lipid-based nutrient supplements; PR, prevalence ratio. Individual study prevalence estimates were extracted from published material and prevalence ratios were pooled using inverse-variance weighting with random effects. For Adubra (27, 28), values are based on a combined weighted average of the mean change for the SNACK+LNS and SNACK + CASH + LNS groups vs the combined weighted average of the mean change for the SNACK and SNACK + CASH groups. For Soofi (Sindh) (30), PRs were calculated after recalibrating the endline prevalence differences to take into account the intervention group difference already present at 6 mo, so the effect estimates are related only to the effects of child supplementation.

Figure 3: Forest plot of effect of MQ-LNS vs. control on stunting prevalence. MQ-LNS, medium-quantity lipid-based nutrient supplements; PR, prevalence ratio. Individual study prevalence estimates were extracted from published material and prevalence ratios were pooled using inverse-variance weighting with random effects. For Soofi (Sindh) (30), PRs were calculated after recalibrating the endline prevalence differences to take into account the intervention group difference already present at 6 mo, so the effect estimates are related only to the effects of child supplementation.

Supplemental Figure 1: Summary risk of bias as a percentage of all included studies for the effects of MQ-LNS on growth outcomes. MQ-LNS, medium-quantity lipid-based nutrient supplements

Supplemental Figure 2: Forest plot of effect of MQ-LNS vs. control on change in WLZ. MQ-LNS, medium-quantity lipid-based nutrient supplements; WLZ, weight-for-length z-score.

Individual study difference-in-difference estimates were extracted from published material and pooled using inverse-variance weighting with random effects. For Adubra (27, 28), values are based on a combined weighted average of the mean change for the SNACK+LNS and SNACK + CASH + LNS groups vs the combined weighted average of the mean change for the SNACK and SNACK + CASH groups. For Soofi (Sindh) (30), values were based on the change in z-scores between 6 and 24 mo (using an approximation of the SD).

Supplemental Figure 3: Forest plot of effect of MQ-LNS vs. control on change in LAZ. MQ-LNS, medium-quantity lipid-based nutrient supplements; LAZ, length-for-age z-score.

Individual study difference-in-difference estimates were extracted from published material and pooled using inverse-variance weighting with random effects. For Soofi (Sindh) (30), values were based on the change in z-scores between 6 and 24 mo (using an approximation of the SD).

Supplemental Figure 4: Forest plot of effect of MQ-LNS vs. control on change in WAZ. MQ-LNS, medium-quantity lipid-based nutrient supplements; WAZ, weight-for-age z-score.

Individual study difference-in-difference estimates were extracted from published material and pooled using inverse-variance weighting with random effects. For Soofi (Sindh) (30), values were based on the change in z-scores between 6 and 24 mo (using an approximation of the SD).

Supplemental Figure 5: Forest plot of effect of MQ-LNS vs. control on underweight prevalence.

MQ-LNS, medium-quantity lipid-based nutrient supplements; PR, prevalence ratio. Individual study prevalence estimates were extracted from published material and prevalence ratios were pooled using inverse-variance weighting with random effects. Pooled estimates were generated using inverse-variance weighting with both fixed and random effects. For Soofi (Sindh) (30),

PRs were calculated after recalibrating the endline prevalence differences to take into account the intervention group difference already present at 6 mo, so the effect estimates are related only to the effects of child supplementation.

Figure 1. Study Flow Diagram



